Immunotherapy in human colorectal cancer: Challenges and prospective

doi:10.3748/wjg.v22.i28.6362

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 28

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8506)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

1079

WORD

252

HTML

5197

Tables (1-3)

162

Sum=6690

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

871

Download

945

Sum=1816

Jul 28, 2016 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (36)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jul 28, 2016; 22(28): 6362-6372
Published online Jul 28, 2016. doi: 10.3748/wjg.v22.i28.6362

Table 3 Ongoing immunotherapy clinical trials in human colorectal cancer

Type	Cancer	Phase	Name	Identifier	Start time
Monoclonal antibodies	Untreated metastatic colorectal cancer	II	RO5520985 (a bispecific anti-ANG-2/anti-VEGF-A	NCT02141295	5/15/2014
	Colorectal cancer	I/II	IMMU-132 (an Ab-drug conjugate targeting Τrop-2)	NCT01631552	6/26/2012
	Metastatic colorectal cancer	I/II	IMMU-130 (an Ab-drug conjugate targeting CEACAM5)	NCT01605318	5/22/2012
	Metastatic colorectal carcinoma	I	MGD007 (a dual-affinity re-targeting DART protein designed to target the glycoprotein A33)	NCT02248805	9/18/2014
	Metastatic colorectal cancer	I	OMP-131R10 (an anti-RSPO3 Ab)	NCT02482441	6/19/2015
Immune checkpoint inhibitors	MSI positive/negative colorectal cancer	II	MK-3475 (an Ab that blocks negative signals on T cells)	NCT01876511	6/10/2013
	MSI positive colorectal cancer	I	Ipilimumab	NCT02060188	12/18/2013
	MSI negative colorectal cancer	II	Nivolumab	NCT02060188	12/18/2013
	Colorectal cancer	I	MED14736	NCT01975831	10/29/2013
	Colon cancer	I/II	Anti-CD27 (Varlilumab) and Nivolumab	NCT02335918	12/18/2014
Cancer vaccines	Metastatic colorectal cancer	II	DC vaccine	NCT02615574	11/24/2015
	Colorectal cancer	I	AVX701 (targets CEA)	NCT01890213	6/26/2013
	Metastatic colorectal carcinoma	I	SGI-110 in combination with an allogeneic colon cancer cell vaccine (GVAX) and cyclophosphamide (CY)	NCT01966289	10/10/2013
	Colorectal cancer	I	HER-2 vaccine	NCT01376505	6/9/2011
Adoptive cell therapy	Metastatic colorectal cancer	II	TIL (tumor-infiltrating lymphocytes)	NCT01174121	7/31/2010
	Colorectal cancer	I/II	Anti-MAGE-A3-DP4 TCR	NCT02111850	4/9/2014
	Colorectal carcinoma	I/II	CAR T cells	NCT02617134	11/26/2015
	Colorectal cancer	I	NK cells + CliniMACs CD3 and CD56 systems	NCT00720785	7/22/2008
Oncolytic virus therapies	KRAS mutant metastatic Colorectal cancer	I	REOLYSIN in combination with FOLFIRI and Bevacizumab	NCT01274624	1/7/2011
Adjuvant immunotherapies	Recurrent colorectal cancer	I/II	Chemokine modulatory regimen	NCT01545141	2/29/2012
Cytokines	Colorectal carcinoma	I	AM0010 (a recombinant human IL-10)	NCT02009449	12/2/2013
	Colorectal carcinoma	I	Rh IL-15	NCT01572493	4/5/2012

Citation: Sun X, Suo J, Yan J. Immunotherapy in human colorectal cancer: Challenges and prospective. World J Gastroenterol 2016; 22(28): 6362-6372
URL: https://www.wjgnet.com/1007-9327/full/v22/i28/6362.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i28.6362